Preetesh Jain, MD, PhD, discusses the efficacy and predictors of response with ibrutinib and rituximab in combination as treatment of patients with previously untreated mantle cell lymphoma.
Preetesh Jain, MD, PhD
Advertisement
Articles by Preetesh Jain, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
